Oxford Genetics Receives $500,000 in Innovate UK Funding
Oxford Genetics, a leader in innovative synthetic biology-based technologies, today announces $500,000 in funding from Innovate UK to support the development of its mammalian display antibody discovery technology.
In collaboration with an Oxford-based biopharma company, Oxford Genetics is working to discover novel antibodies against human proteins, for immunotherapy applications. Unlike traditional methods of discovering new antibodies which use animal, bacterial or yeast cells, Oxford Genetics approach uses new technology that allows the discovery of antibodies against human proteins in their naturally occurring state. Furthermore, the use of mammalian systems for discovery and development stages reduces the historically high attrition rate of new drugs when switching from conventional discovery methods to final evaluation in human cells.
The grant will support the development of Oxford Genetics proprietary technology and will use machine learning and complex statistical approaches to develop improved libraries for antibody discovery. The project will also make use of Oxford Genetics custom-built robotics platform, developed as part of a previous Innovate UK grant. With MarketsandMarkets forecasting the immunotherapy drugs market to be worth $201.52 Billion by 2021, the advancement of technology to underpin its development is crucial.
Ryan Cawood, Chief Executive Officer at Oxford Genetics commented, “We are incredibly pleased to announce this new Innovate UK funded R&D program, following on from our previously announced joint project with Oxford University to develop improved bioproduction systems. This grant demonstrates that Oxford Genetics is playing a key role in providing the next-generation antibody discovery services for our biopharmaceutical clients and this will open up a range of new collaborations with other industry partners.”
Len Seymour, Professor of Gene Therapy at the University of Oxford added ‘I am excited to continue working with Oxford Genetics, building on our existing successes in the field. Antibody mammalian display technology is vital in immunotherapy and we are proud to be at the centre of its development.”
This article has been republished from materials provided by Oxford Genetics. Note: material may have been edited for length and content. For further information, please contact the cited source.
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Antibody Drug-Conjugate to Target Treatment-Resistant Childhood LeukemiaNews
Researchers have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia. Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment.
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018